NCT03906331
Approved For Marketing
Not Applicable
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
ConditionsNon Small Cell Lung CancerMedullary Thyroid CancerColon CancerBreast CancerPancreatic CancerPapillary Thyroid CancerOther Solid Tumors With Evidence of Activating RET Alteration
DrugsSelpercatinib
Overview
- Phase
- Not Applicable
- Status
- Approved For Marketing
- Sponsor
- Eli Lilly and Company
- Locations
- 61
Overview
Brief Summary
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Detailed Description
N/A for expanded access
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib
- •Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy
- •Have adequate organ function
Exclusion Criteria
- •Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor
- •Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds
Investigators
Study Sites (61)
Loading locations...
Similar Trials
No Longer Available
Not Applicable
Expanded Access to RXDX-105 for Cancers With RET AlterationsCancers With RET AlterationsNCT03052569Hoffmann-La Roche
No Longer Available
Not Applicable
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET InhibitorCarcinoma, Non-Small-Cell LungThyroid NeoplasmsNCT05225259Eli Lilly and Company
Unknown
Not Applicable
Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System InjuriesNCT03631056Humacyte, Inc.
Terminated
Phase 1
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid TumorsCancerNeoplasmNCT04717375Sanofi125
Available
Not Applicable
Expanded Access to TriheptanoinLong Chain Fatty Acid Oxidation DisordersNCT03773770Ultragenyx Pharmaceutical Inc